These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18215350)

  • 1. Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.
    Geng CM; Ding HL
    Acta Pharmacol Sin; 2008 Feb; 29(2):211-6. PubMed ID: 18215350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
    Geng CM; Ding HL
    Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.
    Ohnishi Y; Tamura Y; Yoshida M; Tokunaga K; Hohjoh H
    PLoS One; 2008 May; 3(5):e2248. PubMed ID: 18493311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing siRNA that distinguish between genes that differ by a single nucleotide.
    Schwarz DS; Ding H; Kennington L; Moore JT; Schelter J; Burchard J; Linsley PS; Aronin N; Xu Z; Zamore PD
    PLoS Genet; 2006 Sep; 2(9):e140. PubMed ID: 16965178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites.
    Du Q; Thonberg H; Wang J; Wahlestedt C; Liang Z
    Nucleic Acids Res; 2005; 33(5):1671-7. PubMed ID: 15781493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.
    Wang H; Ghosh A; Baigude H; Yang CS; Qiu L; Xia X; Zhou H; Rana TM; Xu Z
    J Biol Chem; 2008 Jun; 283(23):15845-52. PubMed ID: 18367449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the RNA Interference Activity Using Central Mismatched siRNAs and Acyclic Threoninol Nucleic Acids (aTNA) Units.
    Alagia A; Terrazas M; Eritja R
    Molecules; 2015 Apr; 20(5):7602-19. PubMed ID: 25919280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [RNAi and neurological disease].
    Yokota T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing of highly effective complementary and mismatch siRNAs for silencing a gene.
    Ahmed F; Raghava GP
    PLoS One; 2011; 6(8):e23443. PubMed ID: 21853133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity.
    Kubo T; Yanagihara K; Takei Y; Mihara K; Morita Y; Seyama T
    Mol Pharm; 2011 Dec; 8(6):2193-203. PubMed ID: 21985606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs.
    Hamada M; Ohtsuka T; Kawaida R; Koizumi M; Morita K; Furukawa H; Imanishi T; Miyagishi M; Taira K
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):301-9. PubMed ID: 12477280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of assembly of siRNA elements into RNA-induced silencing complex by fork-siRNA duplex carrying nucleotide mismatches at the 3'- or 5'-end of the sense-stranded siRNA element.
    Ohnishi Y; Tokunaga K; Hohjoh H
    Biochem Biophys Res Commun; 2005 Apr; 329(2):516-21. PubMed ID: 15737617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing.
    Dua P; Yoo JW; Kim S; Lee DK
    Mol Ther; 2011 Sep; 19(9):1676-87. PubMed ID: 21673662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of siRNA terminal mismatches on TRBP and Dicer binding and silencing efficacy.
    Kini HK; Walton SP
    FEBS J; 2009 Nov; 276(22):6576-85. PubMed ID: 19811537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs.
    Huang H; Qiao R; Zhao D; Zhang T; Li Y; Yi F; Lai F; Hong J; Ding X; Yang Z; Zhang L; Du Q; Liang Z
    Nucleic Acids Res; 2009 Dec; 37(22):7560-9. PubMed ID: 19815667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference.
    Abdelgany A; Wood M; Beeson D
    Hum Mol Genet; 2003 Oct; 12(20):2637-44. PubMed ID: 12928480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.